ZURICH – Faster drug approval policy adopted by Chinese regulators has benefited the drug industry considerably.
Roche’s Alecensa cancer medicine the latest beneficiary of the fast drug approval policy of China has also benefited hugely – in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans.
China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.